We have located links that may give you full text access.
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Impact of periprocedural myonecrosis on clinical events after implantation of drug-eluting stents.
International Journal of Cardiology 2008 October 14
BACKGROUND: High level of creatine kinase myocardial band isoenzyme (CK-MB) elevation has been associated with late mortality after coronary intervention. We sought to evaluate the impact of periprocedural myonecrosis on clinical events in patients undergoing drug-eluting stents (DES) implantation.
METHODS: A total of 1807 patients (2550 lesions) with successful DES implantation were followed for mean duration of 13 + or - 7 months. Patients with acute myocardial infarction and those with elevated CK-MB at baseline were excluded. Based on the CK-MB levels after stenting, patients were classified into three groups: group I: normal CK-MB (n=1429, 79.1%), group II: 1 to 5 times normal CK-MB (n=263, 14.6%), and group III: >5 times normal CK-MB (n=115, 6.4%). Major adverse cardiac events (MACE) were defined as cardiac death, myocardial infarction, and target lesion revascularization.
RESULTS: With increasing levels of periprocedural CK-MB, there was an increased incidence of MACE (5.0% in group I vs. 6.1% in group II vs. 10.4% in group III, p=0.010) and cardiac death (0.5% in group I vs. 1.1% in group II vs. 2.6% in group III, p=0.016). By multivariate analysis, periprocedural peak CK-MB level was independent predictor of MACE (hazard ratio 1.01, 95% confidence interval 1.00 to 1.03; p=0.044).
CONCLUSIONS: Periprocedural myonecrosis was significantly associated with subsequent adverse clinical events after DES implantation.
METHODS: A total of 1807 patients (2550 lesions) with successful DES implantation were followed for mean duration of 13 + or - 7 months. Patients with acute myocardial infarction and those with elevated CK-MB at baseline were excluded. Based on the CK-MB levels after stenting, patients were classified into three groups: group I: normal CK-MB (n=1429, 79.1%), group II: 1 to 5 times normal CK-MB (n=263, 14.6%), and group III: >5 times normal CK-MB (n=115, 6.4%). Major adverse cardiac events (MACE) were defined as cardiac death, myocardial infarction, and target lesion revascularization.
RESULTS: With increasing levels of periprocedural CK-MB, there was an increased incidence of MACE (5.0% in group I vs. 6.1% in group II vs. 10.4% in group III, p=0.010) and cardiac death (0.5% in group I vs. 1.1% in group II vs. 2.6% in group III, p=0.016). By multivariate analysis, periprocedural peak CK-MB level was independent predictor of MACE (hazard ratio 1.01, 95% confidence interval 1.00 to 1.03; p=0.044).
CONCLUSIONS: Periprocedural myonecrosis was significantly associated with subsequent adverse clinical events after DES implantation.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app